Is Retatrutide Legal? US, UK, Canada and Australia

Is retatrutide legal? Only in two settings: a clinical trial, or Lilly's narrow expanded access program. Selling it is illegal in the US, the UK, Canada and Australia, because no regulator anywhere has approved it, and Lilly says "no one can legally sell it for human use." So if you're asking whether you can legally buy retatrutide from a website, the answer as of October 2026 is no. Owning a vial is murkier, and that's where the 4 countries differ.

None of this is legal advice. It's what each regulator has published, with dates, and where the rules go quiet.

Why is retatrutide illegal to sell?

A drug needs approval before anyone can market it, and retatrutide doesn't have one. In the US, the Federal Food, Drug, and Cosmetic Act bars putting a new drug into interstate commerce without an approved application (21 U.S.C. § 331(d), which points to § 355). A first offense carries up to 1 year in prison, a $1,000 fine, or both. With intent to defraud or mislead, it's up to 3 years, $10,000, or both, under 21 U.S.C. § 333. Those are the statute's printed fines; the general federal fine law (18 U.S.C. § 3571) can allow higher ones.

Lilly's own wording is blunter. Its July 23, 2026 release calls retatrutide "an investigational molecule that cannot be legally sold or marketed for human use." Its October 28, 2026 release adds: "Anyone purporting to sell retatrutide to consumers is breaking the law." Lilly's FAQ, updated in October 2026, says retatrutide "has not been reviewed or approved by the FDA or any regulatory agency in the world."

The FDA has closed the side door too. Its page on unapproved GLP-1 drugs (current as of October 1, 2026) says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." That rules out the pharmacy route people used for tirzepatide and semaglutide during the shortages.

In the US, retatrutide isn't a controlled substance. It doesn't appear on the DEA's alphabetical list of controlled substances (the version dated August 2026), so it isn't illegal the way a street drug is, and owning it sits in a gray area.

Is retatrutide legal in the US, UK, Canada and Australia?

No, in all 4. Here's what each regulator has said in writing, and the latest action we could confirm.

United States

Selling is the clear part. In December 2024 the FDA posted 4 warning letters over unapproved GLP-1 products that included semaglutide, tirzepatide and/or retatrutide. It called retatrutide an unapproved new drug in a March 31, 2026 letter to an online peptide seller, and again on August 24, 2026 over a product sold as "GLP-3 Reta (Retatrutide)."

Buying is less clear-cut. The FDA's personal importation page says it's illegal "in most circumstances" to import drugs for personal use, then lists narrow cases where it may look the other way. For a serious condition, all of these have to apply: effective treatment may not be available in the US, the product isn't promoted to US residents, it poses no unreasonable risk, you confirm in writing it's for personal use, the amount is generally no more than a 3-month supply, and you name your US doctor (or show the treatment began abroad). Approved weight-loss drugs exist in the US, so in our read the first test is hard to meet for weight loss. We found no public case of the FDA prosecuting someone for buying retatrutide for their own use. State drug and pharmacy laws vary, and we haven't checked all 50.

United Kingdom

The MHRA's July 24, 2026 warning names retatrutide directly: "It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally." It seized more than 2,000 unlicensed retatrutide and tirzepatide pens in Northampton in October 2025, then arrested 2 people and recovered about 12,000 doses near the same town on May 29, 2026, its largest such seizure. Its December 2025 warning tells buyers not to buy prescription-only medicines without a prescription. We couldn't find an MHRA statement on simply owning retatrutide.

Canada

Health Canada's April 9, 2026 advisory lists retatrutide among unauthorized injectable peptides it has seized, and says unauthorized drug products "are illegal in Canada." It tells people to look for an 8-digit Drug Identification Number (DIN) on any drug they buy, and retatrutide has none. Peptides are generally regulated as prescription drugs there, and Health Canada's personal import guidance (GUI-0116, updated July 13, 2026) says residents generally aren't allowed to bring prescription drugs into Canada, in person or by mail, and that non-compliant health products "will be refused entry or seized."

Australia

The TGA's September 14, 2026 alert says retatrutide isn't approved by the TGA or any comparable overseas regulator, and that any product outside a trial could be counterfeit. Supplying unapproved therapeutic goods is prohibited unless an exemption applies, with penalties up to $1.82 million per breach for a person and 7 years in prison. The TGA's April 13, 2026 peptide advisory names retatrutide and says vials that are unlabeled, coded or unclear about what's inside "will not be considered for release" under the Personal Importation Scheme, and that state and territory laws may add controls on possession. The scheme page (updated September 8, 2026) requires a valid Australian prescription for prescription-only imports.

Mexico and the rest of the world

Lilly says no regulator in the world has approved retatrutide, so no country has a legal retail market. We found no statement from Mexico's regulator, COFEPRIS, on a personal vial. For more countries, see retatrutide availability by country.

Can you get in trouble for buying or owning a vial?

Every enforcement action we found targets sellers.

A label disclaimer doesn't help. The FDA has warned companies that sold retatrutide with labels claiming it wasn't meant for people, while selling it to consumers with dosing instructions. Health Canada says such labels don't make a product legal, and the TGA says a disclaimer alone doesn't change a product's status or permit its import.

A US doctor can't legally supply it either, outside the trial and expanded access routes; how to get retatrutide walks through every route.

Our read: with every case aimed at sellers, the likelier legal cost to a buyer is a seized package and no refund (the TGA says none is paid), not a prosecution. The medical risk is bigger, as the lab tests and liver cases below show.

Retatrutide lawsuits and the gray market crackdown

On August 12, 2026, Lilly filed 6 lawsuits against US sellers of retatrutide, a mix of compounding pharmacies, medical spas and online peptide sellers, in federal courts in California and Texas. The defendants are Aesthetic Envy (N.D. Cal.), Astra Peptides and Texas Peptides (W.D. Tex.), Legendary Peptides (E.D. Tex.), and Striker Pharmacy and Lone Star Peptide Co. (S.D. Tex.). The same day it said it had referred more than 200 people and companies to the FDA, the Department of Justice, state attorneys general, police and licensing boards, and reported more than 14,000 websites, ads, posts and listings in more than 100 countries. None of the 6 suits targets a buyer.

Lilly's counterfeit-medicines page adds that federal prosecutors in Florida have filed criminal proceedings against someone selling illicit "retatrutide" that tested as a different active ingredient. It gives no case name or date. Secondary reports mention more Lilly suits in October and some settlements, but we found no Lilly release or docket for them, so we don't count them. Lilly asks people to report illegal retatrutide to regulators, law enforcement or the Lilly Answers Center at 1-800-LillyRx. Our Eli Lilly retatrutide page tracks Lilly's side.

What regulators found inside the vials

In September 2026, the TGA tested an unmarked vial sold as retatrutide after a person had uncontrollable vomiting, a torn esophagus and a hospital stay. It held no retatrutide, only semaglutide at about 8 times the level in approved semaglutide products. In Victoria, the Chief Health Officer's June 19, 2026 alert covers 6 cases of acute (sudden) liver injury since January 2026 in people who used an unapproved product labeled Retatrutide. Our is retatrutide safe page covers the medical side, and retatrutide for sale covers lab reports and red flags.

The legal ways to get retatrutide

Before approval there are 2 routes: a clinical trial, or Lilly's expanded access program.

When we pulled the ClinicalTrials.gov registry on October 31, 2026, 33 retatrutide studies were listed and 2 were recruiting. One is Lilly's SYNERGY-Outcomes study for adults with fatty liver disease (MASLD) at higher risk of complications. It lists 563 sites in 34 countries or territories; 502 are recruiting, 137 of them in the US. The other is a Phase 2 listing from Hudson Biotech, not Lilly, at 1 site in Shenzhen, China. In a placebo-controlled trial, you may not get the drug. The retatrutide clinical trials page tracks what's open, and retatrutide trials near me sorts sites by place.

Expanded access is the second, and it's narrow. Lilly's single-patient program (NCT07629401) is for adults whose BMI is still 35 or more on the highest available dose of an approved weight-loss drug, who have at least 2 serious or life-threatening obesity-related complications, and who can't join a trial. Availability depends on geography, supply and a review of each patient. Your doctor contacts the Lilly Answers Center; Lilly asks patients not to call directly.

After that comes approval. Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026. The retatrutide release date page works through when a pharmacy could fill it.

Zepbound (tirzepatide) and Wegovy (semaglutide) are approved and legal with a prescription. Zepbound starts at $299 a month self-pay for the KwikPen or vials through LillyDirect, and Wegovy pens are $349 a month self-pay after Novo's 2-month starter offer, which runs through December 31, 2026.

Rumors, "government protocols" and what would change the answer

We found no "government protocol" for retatrutide from any government; the only formal protocols are the trial protocols on ClinicalTrials.gov. The government program people may mean is Medicare's GLP-1 Bridge, which covers Zepbound KwikPen, Foundayo or Wegovy at $50 a month through 2027. It doesn't include retatrutide.

The court record on retatrutide's legal classification is narrower than the rumors. The case is Lilly's own suit against the FDA, filed September 3, 2024 in federal court in Indiana, over whether retatrutide is a drug or a biologic. Lilly appealed to the Seventh Circuit, and on September 24, 2026 the panel ordered both sides to file briefs on whether it can hear the appeal at all. The government's October 8 brief says "Lilly cannot appeal a district court's order remanding to an agency." Lilly's answer is that the appeal is the only proceeding that can address the question.

Either way, the case settles which application Lilly files, not whether a vial bought online is legal. Our FDA approval page covers the case and the filing timeline.

Our read: if the FDA approves Lilly's retatrutide, it'll be legal with a prescription, but that won't make gray market vials legal, any more than approval made online tirzepatide vials legal. The FDA has warned sellers of those too. New regulator actions and filing news go on the retatrutide news page.